Drug Trial Radar · NCT05950464
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Dec 18, 2023
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Jul 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
Conditions
- Recurrent Endometrial Carcinoma
- Recurrent Endometrial Clear Cell Adenocarcinoma
- Recurrent Endometrial Endometrioid Adenocarcinoma
- Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694Drug
Given PO
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
TuvusertibDrug
Given PO
X-Ray ImagingProcedure
Undergo x-ray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (DLTs) (Part I)Time frame: Within the first cycle of study treatment (up to 28 days)
- DLTs (Part II)Time frame: Within the first 2 cycles of study treatment (up to 56 days)
- Measurements for gammaH2AX (PART II)Time frame: Baseline and cycle 1, day 8 (C1D8)
- Incidence of adverse events (Part I and II)Time frame: Up to 5 years
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Augusta University Medical Center
Augusta, Georgia · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa · Recruiting
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan · Recruiting
University of New Mexico Cancer Center
Albuquerque, New Mexico · Recruiting
Case Western Reserve University
Cleveland, Ohio · Active not recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
NRG Oncology
Philadelphia, Pennsylvania · Recruiting
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
Women and Infants Hospital
Providence, Rhode Island · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.